GRFS (Grifols) Ending Cash Position: $812 Mil (As of Mar. 2026)


GRFS Grifols SA GRFS
82 GF Score
Price $7.26
GF Value $9.79
Valuation Modestly Undervalued
! 7 Warning Signs
View Full Analysis

What is Grifols Ending Cash Position?

Grifols GRFS -0.48% 82 Ending Cash Position is $812 Mil as of Mar. 2026. GuruFocus rates GRFS with a GF Score™ of 82/100 and a GF Value™ of $9.79 (Modestly Undervalued). The stock has 7 warning signs investors should review.

Grifols's Ending Cash Position for the quarter that ended in Mar. 2026 was $812 Mil.

Grifols's quarterly Ending Cash Position increased from Sep. 2025 ($729 Mil) to Dec. 2025 ($966 Mil) but then declined from Dec. 2025 ($966 Mil) to Mar. 2026 ($812 Mil).

Grifols's annual Ending Cash Position increased from Dec. 2023 ($577 Mil) to Dec. 2024 ($1,026 Mil) but then declined from Dec. 2024 ($1,026 Mil) to Dec. 2025 ($966 Mil).

Grifols Ending Cash Position Related Terms

Grifols Ending Cash Position Historical Data

* Premium members only.

The historical data trend for Grifols's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Grifols Ending Cash Position Chart

Grifols Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Ending Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3,023.29 581.79 576.88 1,026.18 966.04

Grifols Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Dec21 Jun22 Sep22 Dec22 Jun23 Sep23 Dec23 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 814.05 644.40 728.83 966.04 811.56
GRFS
82GF Score
Grifols SA GRFS
Ending Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Grifols Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Grifols's Ending Cash Position for the fiscal year that ended in Dec. 2025 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=1147.541+-181.499
=966

Grifols's Ending Cash Position for the quarter that ended in Mar. 2026 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=953.757+-142.196
=812

Frequently Asked Questions Learn more about Ending Cash Position →
What does a Ending Cash Position of $812 Mil mean?
Grifols (GRFS) has a Ending Cash Position of $812 Mil as of Mar. 2026. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Grifols and its competitors.
Is Grifols' Ending Cash Position too high?
Grifols' current Ending Cash Position is $812 Mil. Overall, Grifols has a GF Score™ of 82/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Grifols' Ending Cash Position compare to LLY and JNJ?
Grifols' Ending Cash Position of $812 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Drug Manufacturers company?
A good Ending Cash Position depends on the Drug Manufacturers industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Grifols and its competitors. Grifols's current Ending Cash Position is $812 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Grifols stock overvalued right now?
Based on GuruFocus' analysis, Grifols (GRFS) is currently considered Modestly Undervalued. The stock's GF Value™ is $9.79, compared to a current price of $7.26 — trading 25.9% below its estimated fair value. The current Ending Cash Position is $812 Mil. Grifols' overall GF Score™ is 82/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For Grifols (GRFS), the current Ending Cash Position is $812 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Grifols (GRFS) Overvalued in 2026?

Based on GuruFocus' analysis, Grifols stock appears to be undervalued. The current stock price of $7.26 is trading 25.9% below its estimated GF Value™ of $9.79. GuruFocus considers Grifols to be Modestly Undervalued.

Key valuation signals for GRFS:

  • Ending Cash Position: $812 Mil
  • GF Value™: $9.79 vs. price of $7.26 (25.9% below fair value)
  • GF Score™: 82/100 with 7 warning signs

No single metric tells the full story. See the GRFS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Grifols Business Description

Address Avinguda de la Generalitat, 152-158, Parc de Negocis Can Sant Joan, Sant Cugat del Valles, Barcelona, ESP, 08174
Grifols SA is a healthcare company engaged in activities related to plasma-derived products and diagnostic solutions. The group has four reportable segments: Biopharma, Diagnostic, Bio Supplies, and Others. The Biopharma segment focuses on products derived from human plasma for therapeutic use, while the Diagnostic segment includes the marketing of diagnostic testing equipment and reagents. The Bio Supplies segment covers biological products for non-therapeutic use and plasma sales to third parties, and the Others segment includes manufacturing services, research activities, and complementary pharmaceutical products.
82GF Score

Get the complete analysis for GRFS

Ending Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$7.26
Price
$9.79
GF Value